Pharma Firms Lament Inconsistencies In EU Blood, Tissues & Cells Proposal
Executive Summary
Stakeholders have suggested changes to the draft EU regulation on substances of human origin to ensure there is no interference with pharmaceutical regulatory activities. They also want clarity on the regulation of advanced therapies and a clear hierarchy for entities dealing with borderline cases.